Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point
all to provide the highest quality experience for your patients
IGF-1 LR3 contains a 13-amino-acid N-terminal extension and a glutamic acid substitution at position 3, reducing binding affinity for IGF-binding proteins (IGFBPs) by approximately 100-fold compared to endogenous IGF-1
Rep 76 , 754779 (2024)
45, 371 Pratley, R
US$ 22.00
US$ 28.63
US$ 25.34
US$ 27.26
US$ 25.99
US$ 27.11
US$ 27.81
US$ 23.75
US$ 22.40
